Altimmune to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences:

• 2026 Jefferies Global Healthcare Conference
  Thursday, June 4, 2026
  Fireside chat at 12:50 p.m. ET
  New York, NY
  

• Goldman Sachs 47th Annual Global Healthcare Conference
  Wednesday, June 10, 2026
  Fireside chat at 8:00 a.m. ET
  Miami Beach, FL
  

A webcast of the fireside chats will be available via the Events section of the Altimmune website.

About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead investigational candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X

Investor Contact:
Luis Sanay, CFA
Vice President, Investor Relations
[email protected]

Media Contact:
Real Chemistry
[email protected]

Source: Altimmune, Inc

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Leerink Starts Altimmune (ALT) at Outperform
• Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission
• Samsung Unveils Industry's Fastest UFS 5.0 Solution for Next-Gen On-Device AI Applications